坦昔妥单抗(Tafasitamab-Cxix) - 药物靶点：CD19_在研适应症：复发性滤泡性淋巴瘤，难治性滤泡性淋巴瘤，弥漫性大B细胞淋巴瘤_专利_临床

概要

基本信息

药物类型

单克隆抗体

别名

anti-CD19 MAb XmAb5574、anti-CD19 MoAb XmAb5574、Tafasitamab

+ [13]

靶点

CD19

作用方式

抑制剂

作用机制

CD19抑制剂(B淋巴细胞抗原CD19抑制剂)、ADCC(抗体依赖的细胞毒作用)、抗体依赖的细胞吞噬作用

治疗领域

肿瘤免疫系统疾病血液及淋巴系统疾病+ [1]

在研适应症

复发性滤泡性淋巴瘤难治性滤泡性淋巴瘤弥漫性大B细胞淋巴瘤+ [25]

非在研适应症

难治性套细胞淋巴瘤难治性非霍奇金淋巴瘤难治性弥漫性大B细胞淋巴瘤活化B细胞型

原研机构

Xencor, Inc.

在研机构

Incyte Biosciences Distribution BVBoehringer Ingelheim Pharma GmbH & Co., KG

Incyte Corp.

+ [7]

非在研机构

Xencor, Inc.

权益机构

Incyte Corp.Specialised Therapeutics Asia Pte Ltd.

Knight Therapeutics, Inc.

+ [6]

最高研发阶段批准上市

首次获批日期

美国 (2020-07-31),

难治性弥漫性大 B 细胞淋巴瘤

最高研发阶段(中国)批准上市

特殊审评快速通道 (美国)、加速批准 (美国)、孤儿药 (美国)、孤儿药 (欧盟)、孤儿药 (日本)、孤儿药 (韩国)、孤儿药 (澳大利亚)、附条件批准 (欧盟)、附条件批准 (美国)、附条件批准 (中国)、优先审评 (中国)、突破性疗法 (美国)

登录后查看时间轴

结构/序列

Sequence Code 1697872

来源: *****

Sequence Code 12960725

来源: *****

关联

62

项与坦昔妥单抗相关的临床试验

NCT07582159

/ Not yet recruiting临床2期IIT

A Phase 2 Study of Acalabrutinib, Venetoclax and Tafasitamab (AVT) in Patients With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

This phase II trial tests the safety, side effects and how well giving tafasitamab with acalabrutinib and venetoclax works for the treatment of chronic lymphocytic leukemia (CLL)/small cell lymphoma (SLL). A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Tafasitamab is a monoclonal antibody that binds to CD19 antigen which is found on the surface of most B cells (a type of white blood cell) and some lymphoma cells. This may help the immune system kill cancer cells. Acalabrutinib is in a class of medications called kinase inhibitors. It blocks a protein called BTK, which is present on B-cell (a type of white blood cells) cancers such as mantle cell lymphoma at abnormal levels. This may help keep cancer cells from growing and spreading. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving tafasitamab with acalabrutinib and venetoclax may be safe and effective for treating patients with CLL/SLL.

开始日期2026-12-19

申办/合作机构

City of Hope National Medical Center

[+1]

NCT07731789

/ Not yet recruiting临床2期IIT

TREND-FL: Tafasitamab and Rituximab to Enhance Outcomes in Patients With Newly Diagnosed Follicular Lymphoma

This phase II trial tests how well tafasitamab and rituximab works for the treatment of newly diagnosed follicular lymphoma. Tafasitamab is a monoclonal antibody. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Giving tadasitamab and rituximab may work well to treat patients with newly diagnosed follicular lymphoma.

开始日期2026-10-31

申办/合作机构

University of Washington

[+1]

NCT07225439

/ Not yet recruiting临床1期IIT

Phase I Clinical Trial of Rituximab (Rtx) and Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma

This research study is for people who have relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) that has not responded to two or more lines of therapy. The purpose of this study is to identify the recommended dose of allogeneic NK cells in combination with IL-2, Tafasitamab and Rituximab for the treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma.
NK cells are an investigational (experimental) treatment which means they are not approved by the Food and Drug Administration (FDA). NK cells are a type of lymphocyte that's part of the body's natural immune system, and they can kill cancer cells by creating pores in the cancer cell membranes and inducing apoptosis (programmed cell death).
Participants in this study will receive lymphodepleting chemotherapy, as well as Allogeneic NK cells, Tafasitamab and Interleukin-2 (IL-2) by an intravenous (IV) infusion. Participants are expected to complete one cycle, and they may be eligible to complete a second cycle of the same regiment if they have stable disease, partial or complete remission at the end of the first cycle. Participants will be in this study for about 12 months.

开始日期2026-09-01

申办/合作机构

The Case Comprehensive Cancer Center

[+1]

100 项与坦昔妥单抗相关的临床结果

登录后查看更多信息

100 项与坦昔妥单抗相关的转化医学

登录后查看更多信息

100 项与坦昔妥单抗相关的专利（医药）

登录后查看更多信息

131

项与坦昔妥单抗相关的文献（医药）

2026-07-01·International Journal of Clinical Oncology

Emerging treatment strategies for newly diagnosed diffuse large B-cell lymphoma

Review

作者: Miyazaki, Kana

Abstract:

Despite recent progress in improving patient survival, the outcomes in approximately 40% of patients with diffuse large B-cell lymphoma (DLBCL) remain poor. For many years, R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) has been the standard first-line treatment for DLBCL; however, pola-R-CHP (polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone) has recently emerged as a new treatment option. In parallel, novel molecularly targeted therapies that target signaling pathways, cellular antigens, and epigenetic regulators associated with high-risk DLBCL are in development. Treatment strategies tailored to the cell of origin or to specific molecular subtypes are also being explored using subtype-specific targeted agents. In addition, agents that have demonstrated efficacy in patients with relapsed or refractory DLBCL—such as the anti-CD19 antibody tafasitamab and immunomodulatory drugs such as golcadomide—are currently under investigation for use in newly diagnosed patients. Immunotherapies, including anti-CD19-chimeric antigen receptor-T therapy and CD20×CD3 bispecific antibodies (BsAbs), have significantly improved outcomes in patients with relapsed or refractory disease and are now under evaluation as early-line therapies. BsAbs can enable more flexible treatment strategies, including combination regimens with cytotoxic or chemotherapy-free approaches. This review summarizes recent advances and ongoing trials that are investigating novel therapeutic strategies for newly diagnosed DLBCL that may soon be incorporated into clinical practice.

2026-07-01·ANNALS OF THE RHEUMATIC DISEASES

Successful rescue therapy with the anti-CD19 antibody tafasitamab in anti-MDA5-positive interstitial lung disease suggests therapeutic effects of conventional anti-CD19 antibodies

Letter

作者: Bornhäuser, Martin ; Röber, Nadja ; Aringer, Martin ; Kleymann, Alexander ; Achleitner, Martin ; Koschel, Dirk ; Meisterfeld, Susann ; Schön, Felix

2026-06-01·EUROPEAN JOURNAL OF HAEMATOLOGY

Management of Primary Refractory Diffuse Large B‐Cell Lymphoma in Patients Unsuitable for CAR T‐Cell Therapy

Review

作者: Santino Caserta ; Massimo Gentile ; Eugenio Lucia ; Virginia Olivito ; Francesco Mendicino ; Ernesto Vigna ; Enrica Antonia Martino ; Caterina Labanca ; Nicola Amodio ; Mamdouh Skafi ; Fortunato Morabito ; Maria Eugenia Alvaro ; Antonella Bruzzese

ABSTRACT:

Primary refractory Diffuse Large B‐Cell Lymphoma is associated with poor outcomes and limited responsiveness to conventional salvage therapies. Although CAR T‐cell therapy represents the standard of care in this setting, a substantial proportion of patients cannot receive it despite meeting disease‐related criteria. In this review, “unsuitable” refers to patients who are temporarily or functionally unable to undergo CAR T‐cell therapy because of reversible clinical conditions, rapidly progressive disease requiring immediate cytoreduction, or logistical and social barriers, rather than permanent contraindications. For these patients, prompt alternative strategies are required. Conventional platinum‐based or gemcitabine‐ and bendamustine‐containing regimens retain a role for short‐term disease control but offer limited durability. In contrast, novel antibody‐based therapies, including polatuzumab‐containing combinations, loncastuximab tesirine, and tafasitamab plus lenalidomide, have expanded treatment options with improved tolerability. Most notably, CD20 × CD3 bispecific antibodies represent a major therapeutic advance, providing off‐the‐shelf immune engagement with predominantly outpatient administration. From a practical perspective, early identification of reversible barriers to CAR T‐cell therapy and timely use of bispecific antibodies or other antibody‐based regimens are critical to achieve rapid disease control, preserve organ function, and, when feasible, restore eligibility for cellular therapy.

778

项与坦昔妥单抗相关的新闻（医药）

2026-08-18

·搜狐新闻

诺诚健华涨0.22%，成交额3.35亿元，近5日主力净流入-1.05亿

来源：新浪证券-红岸工作室 8月18日，诺诚健华涨0.22%，成交额3.35亿元，换手率3.89%，总市值561.87亿元。异动分析创新药 1、据招股说明书：公司的主要产品之一奥布替尼（宜诺凯?）已获得国家药监局附条件批准上市用于治疗复发或难治性 MCL 和复发或难治性 CLL/SLL。根据奥布替尼的《药品注册证书》，公司需要在奥布替尼上市后完成 III 期确证性临床试验。在完成上述确证性临床试验后，奥布替尼方能获得完全批准。 (免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断) 资金分析今日主力净流入-965.84万，占比0.03%，行业排名103/157，连续2日被主力资金减仓；所属行业主力净流入-22.73亿，连续3日被主力资金减仓。区间今日近3日近5日近10日近20日主力净流入 -965.84万 -1878.43万 -1.05亿 -4508.34万 -3831.35万主力持仓主力没有控盘，筹码分布非常分散，主力成交额1.31亿，占总成交额的6.27%。技术面：筹码平均交易成本为28.93元该股筹码平均交易成本为28.93元，近期该股获筹码青睐，且集中度渐增；目前股价靠近压力位31.90，谨防压力位处回调，若突破压力位则可能会开启一波上涨行情。公司简介资料显示，诺诚健华医药有限公司位于北京市昌平区中关村生命科学园生命园路8号院8号楼，成立日期2015年11月3日，上市日期2022年9月21日，公司主营业务涉及诺诚健华医药有限公司是一家主要从事生物医药的研发、生产和商业化的中国公司。该公司专注于肿瘤和自身免疫性疾病等存在未满足临床需求的领域，其产品管线包括ICP-022、ICP-B04、ICP-490、ICP-192、ICP-723、ICP-022等。该公司主要在中国和美国开展业务。主营业务收入构成为：药品销售60.73%，技术授权38.07%，研发服务1.11%，检测服务0.09%。诺诚健华所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：肿瘤治疗、抗癌药物、抗癌治癌、创新药、生物医药等。截至3月31日，诺诚健华股东户数2.06万，较上期增加6.49%；人均流通股0股，较上期增加0.00%。2026年1月-3月，诺诚健华实现营业收入5.29亿元，同比增长38.65%；归母净利润1.06亿元，同比增长488.93%。机构持仓方面，截止2026年3月31日，诺诚健华十大流通股东中，富国精准医疗灵活配置混合A（005176）位居第五大流通股东，持股1215.49万股，持股数量较上期不变。汇添富医疗服务灵活配置混合A（001417）位居第八大流通股东，持股467.82万股，相比上期减少109.00万股。东方红医疗升级股票发起A（015052）位居第九大流通股东，持股383.81万股，为新进股东。宝盈医疗健康沪港深股票A（001915）位居第十大流通股东，持股376.56万股，为新进股东。工银前沿医疗股票A（001717）、汇添富创新医药混合A（006113）退出十大流通股东之列。返回搜狐，查看更多

2026-08-18

·BioSpace

InnoCare Announces Approval of Head-to-Head Registrational Phase III Trial of Mesutoclax with Azacitidine versus Venetoclax with Azacitidine in Treatment-Naive AML in China

BEIJING, Aug. 18, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has approved the registrational Phase III study of the Company's novel BCL2 inhibitor mesutoclax (ICP-248) in combination with azacitidine versus venetoclax with azacitidine in elderly or unfit patients with treatment naive (TN) acute myeloid leukemia (AML). The head-to-head randomized, open-label, multicenter registrational Phase III clinical trial is designed to demonstrate the superiority of mesutoclax in combination with azacitidine over venetoclax with azacitidine in elderly or unfit patients with treatment naive AML. The primary endpoint is overall survival (OS). Mesutoclax is a novel, orally bioavailable BCL2 selective inhibitor. BCL2 is an important regulatory protein in the apoptosis pathway, and its abnormal expression is associated with the development of various hematologic malignancies. Mesutoclax exerts anti-tumor activity by selectively inhibiting BCL2 and restoring the normal apoptosis process in cancer cells. Mesutoclax has been granted two Breakthrough Therapy Designations (BTD) by the CDE. Data presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting demonstrated that mesutoclax in combination with azacitidine in patients with AML achieved outstanding efficacy and safety. As of April 13, 2026, among the evaluable TN AML patients, 81.8% achieved composite CR (cCR, CR+CRi). Among patients who achieved overall response, 86.5% were MRD (Minimal Residual Disease) negative. Among cCR responders, 83% achieved cCR in the first treatment cycle, demonstrating that the mesutoclax regimen enables rapid and deep remission. In terms of safety, no dose-limiting toxicities (DLTs) were observed, and the maximum tolerated dose (MTD) was not reached. Notably, both 30-day mortality and 60-day mortality were 0% among TN AML patients. At the recommended dose, the 6-month overall survival (OS) rate was 90.5%. Dr. Jasmine Cui, Co-founder, Chairwoman, and CEO of InnoCare, said, “The efficacy and safety mesutoclax has demonstrated to date give us the confidence to test it head-to-head against the global standard of care. Mesutoclax is one of our key global assets. We have been accelerating the global trial of mesutoclax in combination with azacitidine for AML, with patients enrolled in the U.S. and Australia. We will further advance its clinical development to bring this innovative therapy to more patients worldwide as early as possible.” AML is a malignant hematological disease originating from hematopoietic stem/progenitor cells. The risk of developing AML increases with age and is more common among older adults 1 . About InnoCare Pharma InnoCare (HKEX: 09969; SSE: 688428) is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing innovative drugs for the treatment of cancers and autoimmune diseases, two therapeutic areas with unmet medical needs worldwide. InnoCare has established comprehensive innovation platforms for drug discovery. To date, the Company has developed a robust product pipeline comprising three approved drugs (orelabrutinib, tafasitamab and zurletrectinib), more than ten innovative drug candidates in clinical development, and multiple programs in preclinical stages. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and the United States. For more information about InnoCare, please visit and follow us on LinkedIn. Contact Media Chunhua Lu 86-10-66609879 chunhua.lu@innocarepharma.com Investors 86-10-66609999 ir@innocarepharma.com _________________________________ 1 Technical Guideline for Clinical R&D of New Drugs for Acute Myeloid Leukemia

临床3期ASCO会议突破性疗法临床结果优先审批

2026-08-17

·搜狐新闻

诺诚健华跌0.72%，成交额3.41亿元，近5日主力净流入-6366.55万

来源：新浪证券-红岸工作室 8月17日，诺诚健华跌0.72%，成交额3.41亿元，换手率3.95%，总市值560.63亿元。异动分析创新药 1、据招股说明书：公司的主要产品之一奥布替尼（宜诺凯?）已获得国家药监局附条件批准上市用于治疗复发或难治性 MCL 和复发或难治性 CLL/SLL。根据奥布替尼的《药品注册证书》，公司需要在奥布替尼上市后完成 III 期确证性临床试验。在完成上述确证性临床试验后，奥布替尼方能获得完全批准。 (免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断) 资金分析今日主力净流入-1877.75万，占比0.06%，行业排名138/157，该股当前无连续增减仓现象，主力趋势不明显；所属行业主力净流入-2.77亿，连续2日被主力资金减仓。区间今日近3日近5日近10日近20日主力净流入 -1877.75万 -7517.42万 -6366.55万 -3200.35万 222.00万主力持仓主力没有控盘，筹码分布非常分散，主力成交额1.48亿，占总成交额的5.7%。技术面：筹码平均交易成本为28.82元该股筹码平均交易成本为28.82元，近期该股快速吸筹，短线操作建议关注；目前股价在压力位33.33和支撑位30.29之间，可以做区间波段。公司简介资料显示，诺诚健华医药有限公司位于北京市昌平区中关村生命科学园生命园路8号院8号楼，成立日期2015年11月3日，上市日期2022年9月21日，公司主营业务涉及诺诚健华医药有限公司是一家主要从事生物医药的研发、生产和商业化的中国公司。该公司专注于肿瘤和自身免疫性疾病等存在未满足临床需求的领域，其产品管线包括ICP-022、ICP-B04、ICP-490、ICP-192、ICP-723、ICP-022等。该公司主要在中国和美国开展业务。主营业务收入构成为：药品销售60.73%，技术授权38.07%，研发服务1.11%，检测服务0.09%。诺诚健华所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：肿瘤治疗、抗癌药物、抗癌治癌、创新药、生物医药等。截至3月31日，诺诚健华股东户数2.06万，较上期增加6.49%；人均流通股0股，较上期增加0.00%。2026年1月-3月，诺诚健华实现营业收入5.29亿元，同比增长38.65%；归母净利润1.06亿元，同比增长488.93%。机构持仓方面，截止2026年3月31日，诺诚健华十大流通股东中，富国精准医疗灵活配置混合A（005176）位居第五大流通股东，持股1215.49万股，持股数量较上期不变。汇添富医疗服务灵活配置混合A（001417）位居第八大流通股东，持股467.82万股，相比上期减少109.00万股。东方红医疗升级股票发起A（015052）位居第九大流通股东，持股383.81万股，为新进股东。宝盈医疗健康沪港深股票A（001915）位居第十大流通股东，持股376.56万股，为新进股东。工银前沿医疗股票A（001717）、汇添富创新医药混合A（006113）退出十大流通股东之列。返回搜狐，查看更多

100 项与坦昔妥单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	L01XC	DB15044

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
复发性滤泡性淋巴瘤	美国	MorphoSys US, Inc.	2025-06-18
难治性滤泡性淋巴瘤	美国	MorphoSys US, Inc.	2025-06-18
弥漫性大B细胞淋巴瘤	加拿大	Incyte Corp.	2021-12-06
复发性弥漫性大B细胞淋巴瘤	加拿大	Incyte Corp.	2021-08-19
难治性弥漫性大 B 细胞淋巴瘤	美国	MorphoSys US, Inc.	2020-07-31

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
滤泡性淋巴瘤	临床3期	美国	MorphoSys AG	2022-01-30
T细胞/组织细胞丰富的大B细胞淋巴瘤	临床3期	美国	Incyte Corp.	2021-05-11
T细胞/组织细胞丰富的大B细胞淋巴瘤	临床3期	日本	Incyte Corp.	2021-05-11
T细胞/组织细胞丰富的大B细胞淋巴瘤	临床3期	阿根廷	Incyte Corp.	2021-05-11
T细胞/组织细胞丰富的大B细胞淋巴瘤	临床3期	澳大利亚	Incyte Corp.	2021-05-11
T细胞/组织细胞丰富的大B细胞淋巴瘤	临床3期	奥地利	Incyte Corp.	2021-05-11
T细胞/组织细胞丰富的大B细胞淋巴瘤	临床3期	加拿大	Incyte Corp.	2021-05-11
T细胞/组织细胞丰富的大B细胞淋巴瘤	临床3期	哥伦比亚	Incyte Corp.	2021-05-11
T细胞/组织细胞丰富的大B细胞淋巴瘤	临床3期	捷克	Incyte Corp.	2021-05-11
T细胞/组织细胞丰富的大B细胞淋巴瘤	临床3期	法国	Incyte Corp.	2021-05-11

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05453500 (EHA2026)	临床2期	费城染色体阴性急性淋巴细胞白血病一线 CD19+	29	DA-EPOCH ± RITUXIMAB + TAFASITAMAB	鑰構醖選築範鹽顧鏇蓋(醖糧觸鹽夢餘範蓋襯遞) = 鹹繭壓廠遞憲顧獵鑰繭艱夢選獵選齋艱廠鹹構 (構襯鹽醖齋鬱鏇窪襯繭 ) 更多	积极	2026-05-12
NCT04680052 (inMIND, EHA2026)	临床3期	难治性滤泡性淋巴瘤	548	Tafasitamab + Lenalidomide + Rituximab	膚繭壓簾艱餘鬱鹹襯廠(鏇餘壓糧遞繭艱獵範蓋) = 醖醖遞齋鑰網製糧鏇網醖觸鬱鹹獵範鹽糧壓衊 (夢憲齋襯衊餘鏇醖襯醖, 20.9) 更多	积极	2026-05-12
				Placebo + Lenalidomide + Rituximab	膚繭壓簾艱餘鬱鹹襯廠(鏇餘壓糧遞繭艱獵範蓋) = 艱鏇築鹹糧構觸壓壓廠醖觸鬱鹹獵範鹽糧壓衊 (夢憲齋襯衊餘鏇醖襯醖, 21.6) 更多
EHA2026	N/A	复发性弥漫性大B细胞淋巴瘤二线	54	Tafasitamab plus Lenalidomide (Tafa-Len)	範製網夢選鹽醖網願獵(鏇遞網夢醖積蓋遞鏇鏇) = 膚繭鑰簾蓋簾壓憲積餘窪鹽鑰憲夢構鑰範築淵 (醖夢願繭獵鏇衊夢製醖 ) 更多	积极	2026-05-12
NCT04809467 (topMIND, CTgov)	临床1/2期	慢性淋巴细胞白血病 \| 难治性非霍奇金淋巴瘤	54	tafasitamab+parsaclisib (Cohort 1: R/R DLBCL)	選獵遞繭餘繭繭構選憲 = 壓鹽鑰蓋製憲膚顧築餘鬱憲構鹹鬱積鏇製積憲 (艱製積糧鑰鑰網蓋蓋鏇, 獵鹽窪鬱憲鏇廠築獵選 ~ 齋憲繭糧構蓋製築衊鹹) 更多	-	2026-01-29
				tafasitamab+parsaclisib (Cohort 2: R/R MCL)	選獵遞繭餘繭繭構選憲 = 遞憲襯夢鬱窪襯鹹鑰積鬱憲構鹹鬱積鏇製積憲 (艱製積糧鑰鑰網蓋蓋鏇, 鏇憲繭襯網淵顧繭艱觸 ~ 獵製襯觸選鏇窪鬱選積) 更多
NCT05718869 (ASH2025)	临床2期	慢性淋巴细胞白血病 \| 小淋巴细胞淋巴瘤一线	22	TafasitamabZanubrutinib + TafasitamabZanubrutinib	艱構鑰淵淵艱獵獵積蓋(艱窪壓製鏇淵淵衊範積) = 鏇夢顧襯鏇願夢遞憲襯鹹選簾窪簾願願鑰選積 (艱鑰鏇網醖廠蓋齋膚鏇 ) 更多	积极	2025-12-06
NCT04680052 (inMIND, ASH2025)	临床3期	难治性滤泡性淋巴瘤二线 CD19+ \| CD20+	548	LenalidomideRituximabTafasitamab + LenalidomideRituximabTafasitamabe + LenalidomideRituximabTafasitamab	醖鏇積襯獵鏇選餘繭顧(選遞獵窪繭選窪網壓糧) = 艱觸鹽糧鑰壓膚築範襯餘壓襯願窪選襯艱窪膚 (鹹觸構觸艱蓋積鏇獵繭 ) 更多	积极	2025-12-06
				LenalidomideRituximab + LenalidomideRituximabide + LenalidomideRituximab	醖鏇積襯獵鏇選餘繭顧(選遞獵窪繭選窪網壓糧) = 鹹齋蓋鹽憲築夢獵壓壓餘壓襯願窪選襯艱窪膚 (鹹觸構觸艱蓋積鏇獵繭 ) 更多
NCT05351593 (ASH2025)	临床1/2期	复发性中枢神经系统淋巴瘤	9	Tafasitamab plus lenalidomide	壓繭製膚衊鹽繭蓋餘糧(鬱鹽鏇鹽襯壓觸遞選淵) = febrile neutropenia associated with urinary tract infection 網積襯糧蓋鹽製鏇鬱構 (願構餘醖鹹醖鹹網壓製 )	积极	2025-12-06
NCT04978584 (Smart Stop, ASH2025)	临床2期	弥漫性大B细胞淋巴瘤一线	61	Lenalidomide+Tafasitamab+Rituximab+Acalabrutinib (2 cycles of CHOP)	夢廠網積積鹹鑰淵網蓋(壓淵窪艱觸淵網鹽遞蓋) = 鹹襯鏇窪遞獵壓觸餘壓顧獵憲網願餘築糧鏇夢 (獵積憲醖鏇窪鏇簾選淵 ) 更多	积极	2025-12-06
				Lenalidomide+Tafasitamab+Rituximab+Acalabrutinib (no cycles of CHOP)	夢廠網積積鹹鑰淵網蓋(壓淵窪艱觸淵網鹽遞蓋) = 鏇願壓顧願網糧艱膚齋顧獵憲網願餘築糧鏇夢 (獵積憲醖鏇窪鏇簾選淵 ) 更多
NCT04680052 (inMIND, Pubmed \| Lancet)	临床3期	难治性滤泡性淋巴瘤二线	548	Tafasitamab+lenalidomide+rituximab	夢醖齋襯醖襯醖衊壓蓋(艱鑰襯鏇餘窪顧積餘憲) = 窪壓觸構憲鏇觸壓積選夢夢鏇淵製遞顧鬱鏇觸 (廠糧糧願鏇齋鹹鑰積鏇 )	积极	2025-12-01
				Placebo+lenalidomide+rituximab	夢醖齋襯醖襯醖衊壓蓋(襯膚淵鑰網衊鑰蓋窪廠) = 壓襯遞鹹壓製製願憲構餘夢襯繭顧積築壓蓋繭 (鬱築淵鹹鏇構鑰鏇願鹹 ) 更多
L-MIND (ESMO2025)	N/A	弥漫性大B细胞淋巴瘤	236	Tafasitamab combined with lenalidomide	衊顧願鹽衊鑰遞廠顧鏇(窪糧鑰遞遞窪築簾顧夢) = 齋構範齋襯繭繭夢構遞齋襯醖網襯齋窪醖網選 (獵憲築艱簾鏇糧觸蓋鬱 ) 更多	积极	2025-10-17
				Glofitamab	衊顧願鹽衊鑰遞廠顧鏇(窪糧鑰遞遞窪築簾顧夢) = 衊獵餘築夢鹽鏇鬱鑰鹽齋襯醖網襯齋窪醖網選 (獵憲築艱簾鏇糧觸蓋鬱 ) 更多